These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 31303567)

  • 1. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
    Hieronymus F; Lisinski A; Nilsson S; Eriksson E
    Lancet Psychiatry; 2019 Sep; 6(9):745-752. PubMed ID: 31303567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors.
    Hieronymus F; Nilsson S; Eriksson E
    Transl Psychiatry; 2016 Jun; 6(6):e834. PubMed ID: 27271860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J; Fakra E; Blin O
    Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.
    Hieronymus F; Emilsson JF; Nilsson S; Eriksson E
    Mol Psychiatry; 2016 Apr; 21(4):523-30. PubMed ID: 25917369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo.
    Lisinski A; Hieronymus F; Nilsson S; Eriksson E
    Transl Psychiatry; 2022 Apr; 12(1):160. PubMed ID: 35422023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression.
    Hieronymus F; Lisinski A; Nilsson S; Eriksson E
    Mol Psychiatry; 2018 Aug; 23(8):1731-1736. PubMed ID: 29155804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on sertraline in the management of major depressive disorder in elderly patients.
    Muijsers RB; Plosker GL; Noble S
    CNS Drugs; 2002; 16(11):789-94. PubMed ID: 12383038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
    Mallinckrodt CH; Prakash A; Houston JP; Swindle R; Detke MJ; Fava M
    Neuropsychobiology; 2007; 56(2-3):73-85. PubMed ID: 18037817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
    J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
    Jakubovski E; Varigonda AL; Freemantle N; Taylor MJ; Bloch MH
    Am J Psychiatry; 2016 Feb; 173(2):174-83. PubMed ID: 26552940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
    Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
    Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
    Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
    JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.
    Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A
    Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison.
    Matreja PS; Badyal DK; Khosla P; Deswal RS
    Hum Psychopharmacol; 2007 Oct; 22(7):477-82. PubMed ID: 17647298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study.
    Lisinski A; Hieronymus F; Näslund J; Nilsson S; Eriksson E
    Neuropsychopharmacology; 2020 Feb; 45(3):553-560. PubMed ID: 31521062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.
    Feighner JP; Overø K
    J Clin Psychiatry; 1999 Dec; 60(12):824-30. PubMed ID: 10665628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.